Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Samuel A JacobsJames J LeeThomas J GeorgeJames L WadePhilip J StellaDing WangAshwin R SamaFanny PietteKatherine L Pogue-GeileRim S KimPatrick G GavinCorey LipchikHuichen FengYing WangMelanie FinniganBrian F KieselJan H BeumerNorman WolmarkPeter C LucasCarmen J AllegraAshok SrinivasanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
The RP2D of neratinib in this combination was 240 mg/day, which was well tolerated with low incidence of G3 AEs. There were no objective responses; SD was seen at all neratinib doses. HER2 amplification, detectable in both tissue and blood, was more frequent post-anti-EGFR therapy.